Full-Time

Validation Engineer 2

Alphatec Spine

Alphatec Spine

1,001-5,000 employees

Develops and markets spinal surgery solutions

Compensation Overview

$90k - $110k/yr

No H1B Sponsorship

Carlsbad, CA, USA

In Person

Regular and consistent attendance at the primary worksite is required.

Bachelor's, Master's

Category
QA & Testing (2)
,
Required Skills
JIRA
Risk Management

Get referred to Alphatec Spine

See people who can refer or advise you

Requirements
  • Foundational understanding of FDA Quality System Regulations (21 CFR Part 820) and ISO 13485.
  • Foundational understanding of IEC 62304 and IEC 60601 standards.
  • Foundational understanding of ISO 14971 risk management requirements.
  • Familiarity with defect tracking and test management tools such as Jira and Polarion.
  • Working knowledge of test method qualification methods, including Gage R&R and Attribute Agreement Analysis, and competency using desktop laboratory equipment such as function generators and oscilloscopes.
  • Basic to working knowledge of probability and statistics concepts and design of experiments.
  • Experience supporting Design History File documentation and Change Order routing.
  • Exposure to or experience supporting regulatory submissions such as 510(k)s.
  • Demonstrated organizational and time-management skills to support cross-functional project activities.
  • Ability to communicate technical concepts effectively with internal stakeholders and cross-functional team members.
  • Bachelor’s or master’s degree in biomedical engineering or a related field.
  • 2-8 years of experience in verification and validation or systems engineering for medical devices or other regulated industries.
Responsibilities
  • Lead verification and validation activities for assigned projects, ensuring quality, timeline, and compliance expectations are met while working alongside cross-functional teams.
  • Define verification strategies for new product development and author test plans and protocols.
  • Support continuous improvement of verification and validation practices by identifying inefficiencies, implementing process improvements, and participating in cross-functional problem-solving.
  • Create and review design control documentation, ensuring requirements, test plans and protocols, test reports, and traceability meet FDA and internal quality standards.
  • Design, develop, and qualify manual and automated system-level test methods.
  • Perform validation of non-medical-device software tools and supporting systems as required, ensuring appropriate rigor and documentation.
  • Support risk management activities in accordance with ISO 14971 by contributing to hazard analysis, risk controls, and verification of risk mitigations.
  • Collaborate with senior validation engineers and informally assist with onboarding or knowledge sharing for newer team members.
  • Maintain regular and consistent attendance at the primary worksite.
  • Perform other duties as assigned.
Desired Qualifications
  • ASQ Certified Software Quality Engineer or Certified Quality Engineer certification.

Alphatec Spine develops and sells implants, instruments, and integrated technologies for spine surgery, including devices used in fusion procedures and related navigation or imaging systems gained through acquisitions like SafeOp Surgical. During surgery, surgeons use these implants and instruments, often with imaging or navigation tools to plan and guide the procedure, while the implants support fusion and healing. It differentiates itself with a broad product portfolio and enhanced technology through strategic acquisitions, giving it capabilities in navigation and advanced spine solutions beyond a narrow line of implants. Its goal is to improve spinal surgery outcomes and expand access to effective spine-care solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Carlsbad, California

Founded

1990

Get referred to Alphatec Spine

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 4, 2026 Q2 revenue reached $214 million, up 15%, with EBITDA margin 17%.
  • Alphatec raised 2026 adjusted EBITDA guidance to $140 million and kept $882 million revenue.
  • The May 2026 bank facility cut interest expense over $6 million and extends maturity to 2031.

What critics are saying

  • May 2026 EOS installation failures cut guidance and triggered 32% share collapse.
  • Multiple law firms opened securities investigations after Alphatec admitted unfulfilled committed units.
  • Persistent losses and heavy leverage make a second guidance miss existential if hospital adoption slows.

What makes Alphatec Spine unique

  • Alphatec integrates EOS imaging, SafeOp neuromonitoring, and Valence into one spine workflow.
  • EOS Insight adoption lifted implant revenue 32% within six months, per August 2026 management.
  • The company sells proceduralization, not implants alone, tying software, imaging, and surgery together.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Aug 5th, 2026
Alphatec delivers $214M revenue and 53% adjusted EBITDA growth despite biologics headwinds

Alphatec Holdings reported strong Q2 2026 results with total revenue of $214 million, up 15% year-over-year, and surgical revenue of $196 million, up 17%. The medical device company saw adjusted EBITDA rise 53% to $36 million, with margins expanding 420 basis points to 17%. The company added 24% more net new surgeons and posted 20% case volume growth. Gross margin improved 260 basis points to 72.5%, driven by better inventory efficiency and favourable product mix. Alphatec generated positive free cash flow of approximately $1 million in Q2 and raised full-year adjusted EBITDA guidance to $140 million from $134 million previously. However, revenue per case declined 2.7% due to case mix shifts and international growth. The company now expects full-year revenue per case to decline in the low single digits, citing slower biologics attachment improvement.

Yahoo Finance
Jun 11th, 2026
Alphatec grows revenue 25% to $764M but posts $143M loss with 17.2x debt-to-equity ratio

Alphatec, a spine surgery technology company, reported revenue of $764.2 million in FY 2025, up 25% year-over-year, but posted a net loss of $143.4 million. The company's debt-to-equity ratio stands at approximately 17.2x, whilst its current ratio is 2.1x. Stock-based compensation represented roughly 163% of operating cash flow. Inspire Medical Systems specialises in neurostimulation therapy for obstructive sleep apnea patients who cannot use standard breathing machines. The company targets sleep specialists and ENT surgeons globally. Alphatec differentiates itself through an integrated ecosystem using subsidiaries like EOS imaging and SafeOp Surgical, serving primarily the US hospital market whilst expanding into Europe and Japan. Both companies operate in medical technology but represent different maturity levels and financial profiles for investors seeking healthcare device exposure.

Yahoo Finance
Jun 1st, 2026
Alphatec posts 17% surgical revenue growth, cuts interest expenses by $6M with new bank facility

Alphatec Holdings, a medical technology company specialising in spinal surgery solutions, reported strong first-quarter 2026 results with surgical revenue up 17% and total revenue growing 14% to $192 million. The company achieved non-GAAP adjusted EBITDA of $21 million whilst securing a new bank facility that reduces annual interest expenses by over $6 million. Growth was driven by a 21% increase in surgical case volume and 23% rise in net new surgeon users. The company reported an ending cash balance of $140 million and trailing twelve-month free cash flow of $7 million. For full-year 2026, Alphatec expects total revenue of approximately $882 million, representing 15% growth, with adjusted EBITDA projected at $134 million and at least $20 million in free cash flow generation.

Business Wire
May 19th, 2026
Law firm investigates Alphatec after shares plunge 32% on missed EOS revenue guidance

Kirby McInerney LLP is investigating potential securities law violations by Alphatec Holdings and its senior management following a sharp share price decline. On 5 May 2026, Alphatec reported first quarter revenue of $192 million and disclosed that EOS revenue, from its proprietary imaging platform, was $14 million—below internal expectations. The company reduced its full-year 2026 EOS revenue guidance to approximately $77 million from $85 million, citing execution issues with equipment installations. Management stated that "installation timing was a challenge" and the company failed to fulfill committed units. Following the announcement, Alphatec shares fell 32%, from $10.23 to $6.99 per share. No lawsuit has been filed yet, and the investigation is ongoing to determine whether claims may be brought under federal securities laws.

Yahoo Finance
May 7th, 2026
Alphatec shares drop 25% after Q1 miss, analysts cut target to $18 but maintain growth outlook

Alphatec Holdings shares fell 25% to $6.99 following its first-quarter results, which showed revenue of $192 million, falling 2.3% short of analyst estimates. Statutory losses of $0.22 per share were 12% smaller than expected. Following the results, eleven analysts revised their forecasts, maintaining revenue expectations of $881.8 million for 2026, representing 12% growth. They improved loss predictions to $0.52 per share, down from $0.55 previously. However, the average price target fell 26% to $18.00, with individual targets ranging from $11.00 to $25.00. Analysts expect Alphatec Holdings' revenue growth to slow to 16% annually through 2026, down from 28% over the past five years, though this remains above the industry average of 8%.